When evaluating the combined IOP end point , more ranibizumab-treated eyes had 1 or more IOP increase from baseline of 6 mmHg or more or 8 mmHg or more , with concurrent highest IOPs of 21 mmHg or more and 25 mmHg or more versus sham or PDT .